Dr. Nazia Chaudhary -Cancer research- therapy resistance – Best Researcher Award 

ACTREC,TMC - India

Author Profile 

ORCID

🧪 Early academic pursuits

Chaudhary s. nazia's academic journey began with an intense passion for microbiology, which led her to achieve a stellar 80% in her bachelor’s degree from sophia college, university of mumbai, in 2013. she further pursued a master’s degree in microbiology at st. xavier’s college, where she graduated with distinction, securing 73.5% in 2015. her academic foundation set the stage for a doctoral pursuit at the advanced centre for treatment, research, and education in cancer (actrec), where she completed her phd in march 2022. her research explored the intricate mechanisms that promote tumorigenesis and resistance to radio- and chemotherapy.

🧬 Professional endeavors

Nazia embarked on a remarkable career as a dst inspire faculty at actrec-tata memorial centre (tmc). her dedication to understanding cancer biology has been a cornerstone of her professional work. through rigorous experimentation and innovative approaches, she has consistently contributed to advancing research in oncology. her faculty position at actrec underscores her commitment to fostering new scientific breakthroughs and mentoring future researchers in the field.

🔬 Contributions and research focus

Nazia’s research revolves around understanding cancer mechanisms at the molecular level. her phd project provided groundbreaking insights into the pathways that promote tumorigenesis and resistance to treatment in the absence of plakophilin 3. her earlier work includes projects on thermophiles from ganeshpuri hot springs, Cancer research- therapy resistance mitochondrial function regulation, and industrially important thermophilic actinomycetes. her innovative studies highlight her ability to blend fundamental microbiological concepts with cutting-edge biomedical applications.

🏆 Accolades and recognition

Nazia’s groundbreaking research has been recognized through prestigious patents. she is a co-inventor of two patents focused on antibodies against lipocalin-2 and Cancer research- therapy resistance their therapeutic applications. these patents signify her impactful contributions to cancer treatment strategies and her recognition as a key innovator in her field.

🌍 Impact and influence

Nazia’s work has influenced the scientific community by providing deeper insights into tumor biology and therapeutic resistance. her contributions to understanding Cancer research- therapy resistance mitochondrial regulation and cancer pathways have added valuable knowledge to the field of molecular oncology. as a dst inspire faculty, she continues to inspire and guide young researchers, amplifying her influence in shaping the next generation of scientists.

🌟 Legacy and future contributions

With her focus on uncovering novel therapeutic targets and mechanisms in oncology, nazia aims to create a legacy of impactful research that bridges fundamental science and clinical applications. her continued efforts in cancer research promise to deliver innovative solutions that could transform patient care and improve outcomes for those affected by the disease. her dedication to mentorship ensures her knowledge and passion will resonate through the researchers she inspires.

Notable Publications 

  • Title: LCN2 promotes focal adhesion formation and invasion by stimulating Src activation
    Author(s): Bhagya Shree Choudhary; Nazia Chaudhary; Aditi Vijan; Dibita Mandal; Leena Pilankar; Shubham Gawand; Bushra K. Khan; Anusha Shivashankar; Rinki Doloi; Neha Joshi et al.
    Journal: Preprint
  • Title: EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI
    Author(s): Nazia Chaudhary; Bhagya Shree Choudhary; Anusha Shivashankar; Subhakankha Manna; Khyati Ved; Shagufa Shaikh; Sonal Khanna; Jeetnet Barr; Jagruti Dani; Nandini Verma
    Journal: Preprint
  • Title: GPX4-VIM equates a proliferating DTP state in TNBC subtypes with converged vulnerabilities to autophagy and glutathione inhibition
    Author(s): Nazia Chaudhary; Bhagya Shree Choudhary; Sushmita Patra; Shivani Malvankar; Anusha Shivashankar; Eeshrita Jog; Vaishali V. Kailje; Sonal Khanna; Subhakankha Manna; Sarthak Sahoo et al.
    Journal: Preprint
  • Title: Lipocalin 2 inhibits actin glutathionylation to promote invasion and migration
    Author(s): Choudhary BS; Chaudhary N; Shah M; Dwivedi N; P K S; Das M; Dalal SN
    Journal: FEBS Letters
  • Title: The Role of Lipocalin 2 (LCN2) in Regulating Ferroptosis and Therapy Resistance
    Author(s): Rinki Doloi; Nazia Chaudhary; Sorab N. Dalal
    Journal: National Research Scholars' Meet 2021 - Abstracts

Dr. Hui Jia – Tumor chemotherapy resistance – Best Researcher Award

Dr. Hui Jia - Tumor chemotherapy resistance - Best Researcher Award

Shenyang Medical College - China 

Author Profile 

SCOPUS 

Early academic pursuits đź“š

Dr. Hui Jia's journey in traditional chinese medicine began with a solid academic foundation. she earned her bachelor of pharmacy from shenyang pharmaceutical university, which sparked her interest in natural medicine and pharmacology. pursuing further studies, she obtained a master’s degree in traditional chinese medicine from shaanxi university of traditional chinese medicine. in 2021, she completed her ph.d. in traditional chinese medicine from shenyang pharmaceutical university, where her research honed in on the bioactive compounds of medicinal herbs and their therapeutic potential.

Professional endeavors 🏛️

Dr. Jia is currently an associate professor at the school of traditional chinese medicine, shenyang medical college. she has played a key role in shaping the institution’s research focus on herbal medicines and natural products. her dedication to teaching and mentorship is evident, as she actively guides students in exploring the intricate mechanisms of traditional remedies, while leading significant research projects that address major health challenges like drug-resistant cancers.

Contributions and research focus 🔬

Dr. Hui jia’s primary research revolves around understanding the active ingredients of herbs and their molecular mechanisms, particularly in reversing drug Tumor chemotherapy resistance resistance. her work is centered on investigating the key protein targets of natural products. one of her significant contributions is her research on cimigenoside, a bioactive compound from cohosh, and its role in combating drug resistance in triple-negative breast cancer through the γ-secretase/nicd/notch-pxr axis. her innovative approach offers new insights into cancer treatment.

Accolades and recognition 🏅

Through her groundbreaking research, dr. jia has gained recognition in the scientific community. she has secured prestigious grants from both the national natural science foundation of china and liaoning province for her work on cancer drug resistance. her research projects reflect her excellence and leadership in the field of Tumor chemotherapy resistance traditional chinese medicine, addressing complex challenges in cancer treatment and advancing the potential of natural products as therapeutic agents.

Impact and influence 🌍

Dr. jia's research has far-reaching implications, particularly in the realm of cancer therapeutics. her work on Îł-secretase inhibitors and their role in reversing drug resistance in triple-negative breast cancer highlights the importance of integrating traditional medicine with modern science. her studies provide new avenues for Tumor chemotherapy resistance treating difficult cancers, potentially transforming how drug resistance is managed in clinical settings.

Legacy and future contributions đź”®

with her deep-rooted passion for traditional chinese medicine, dr. hui jia is set to leave a lasting legacy in the field. her future contributions are expected to further bridge the gap between traditional herbal medicine and contemporary drug discovery. as she continues to explore the bioactive compounds of natural products and their mechanisms of action, her work will undoubtedly influence future generations of researchers and contribute to innovative cancer therapies.

Notable Publications 

  1. Atorvastatin ameliorates diabetic nephropathy through inhibiting oxidative stress and ferroptosis signaling
    Authors: Zhang, Y., Qu, Y., Cai, R., Ren, F., Zhou, M.-S.
    Journal: European Journal of Pharmacology, 2024, 976, 176699
  2. Inhibition of Îł-secretase/Notch pathway as a potential therapy for reversing cancer drug resistance
    Authors: Feng, M., Santhanam, R.K., Xing, H., Zhou, M., Jia, H.
    Journal: Biochemical Pharmacology, 2024, 220, 115991
  3. The role of angiotensin II activation of yes-associated protein/PDZ-binding motif signaling in hypertensive cardiac and vascular remodeling
    Authors: Xu, Q., Zhuo, K., Zhang, X., Dong, J., Zhou, M.-S.
    Journal: European Journal of Pharmacology, 2024, 962, 176252
  4. Cardiac macrophages in maintaining heart homeostasis and regulating ventricular remodeling of heart diseases
    Authors: Kang, M., Jia, H., Feng, M., Zhang, L., Zhou, M.-S.
    Journal: Frontiers in Immunology, 2024, 15, 1467089
  5. Cigarette smoke-induced exosomal miR-221-3p facilitates M1 macrophage polarization via the STAT3 pathway in chronic obstructive pulmonary disease
    Authors: Jia, H., He, W., Wu, B., Wang, M., Xia, S.
    Journal: Aging, 2024, 16(17), pp. 12379–12391